News Headline Summary
EMA (European Medicines Agency) recommends Roche's (ROG) Perjeta for breast cancer
Reaction details:
- No immediate reaction to the news, last trade at CHF 186.40 (+0.27%)
Print
12:09, 14 Dec 2012 -
SMI
- Source:
Newswires
Subscribe Now to RANsquawk
Click here for a 1 week free trial
RANsquawk provides audio news and commentary for over 15,000
professional traders and brokers worldwide. Services include:
-
Real-time audio coverage from 0630 to 2130 London time
-
Teams of analysts covering equities, fixed income, FX and energy markets
-
Real-time scrolling news service
-
Daily and weekly pre-market research and calendars
-
Intra-day market update videos
-
Daily technical analysis